Related Experiment Video
Updated: Feb 10, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren M Lasko1, Clarissa G Jakob1, Rohinton P Edalji1
1Discovery, Global Pharmaceutical Research and Development, North Chicago, IL, USA.
Abstract:
In the originally published version of this Letter, the authors Arthur F. Kluge, Michael A. Patane and Ce Wang were inadvertently omitted from the author list. Their affiliations are: I-to-D, Inc., PO Box 6177, Lincoln, Massachusetts 01773, USA (A.F.K.); Mitobridge, Inc. 1030 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA (M.A.P.); and China Novartis Institutes for BioMedical Research, No. 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong District, Shanghai 201203, China (C.W.). These authors contributed to the interpretation of results and design of compounds. In addition, author 'Edward A. Kesicki' was misspelled as 'Ed Kesicki'. These errors have been corrected online.
Related Concept Videos
Milgram's Obedience to Authority
Dose-Response Relationship: Selectivity and Specificity
Distance Corrections
Power Factor Correction
Lineage Commitment
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

